Spider Venom Shows Potential as a Treatment for Heart Attacks and Strokes

Spider Venom Shows Potential as a Treatment for Heart Attacks and Strokes

Venom from deadly spiders may pose a threat to humans, but astonishingly, it may also hold the key to saving lives. A team of researchers from the University of Queensland in Australia has made significant progress in exploring the potential of a spider-venom molecule as a treatment for heart attacks and strokes.

Led by Professors Nathan Palpant and Glenn King from the Institute for Molecular Bioscience, the team has previously demonstrated that a drug candidate called Hi1a can protect cells from the damage caused by heart attacks and strokes. Recently published in The European Heart Journal, their latest study has successfully completed a series of preclinical tests that simulate real-life treatment scenarios.

This breakthrough discovery brings us closer to understanding how Hi1a can be used as a therapeutic intervention. The team has found that Hi1a is just as effective in protecting the heart as the only cardioprotective drug that has reached Phase 3 clinical trials. Unlike this drug, which was abandoned due to side effects, Hi1a interacts specifically with the injured area of the heart during an attack, minimizing the risk of adverse reactions in healthy regions.

Professor King, well-known for his groundbreaking work in developing insecticides from spider venom, first identified the potential of Hi1a. He explains that Hi1a could potentially limit heart and brain damage during cardiovascular events by preventing cell death resulting from oxygen deprivation.

Impressively, independent contract research organizations have conducted safety studies that confirm the effectiveness and safety of Hi1a as a potential therapeutic. In light of these promising results, Infensa Bioscience, a company co-founded by the researchers, raised $23 million in funding in 2022 to further develop Hi1a for commercial purposes.

Cardiovascular disease is currently the leading global cause of death, with heart attacks and strokes being major contributors. With no existing drugs on the market to prevent the damage caused by these events, the development of an effective treatment like Hi1a could have a profound impact on millions of individuals suffering from heart disease worldwide.

While spider venom might have once been regarded solely as a danger to humans, this research highlights its hidden potential as a life-saving remedy. As scientists continue to push the boundaries of medical science, nature’s deadliest creations could become unexpected sources of hope and healing.

Frequently Asked Questions (FAQ): Spider Venom as a Treatment for Heart Attacks and Strokes

Q: What is the main focus of the research conducted by the team from the University of Queensland?
A: The team is exploring the potential of a spider-venom molecule, specifically a drug candidate called Hi1a, as a treatment for heart attacks and strokes.

Q: What has the team accomplished in their recent study?
A: The team has successfully completed a series of preclinical tests that simulate real-life treatment scenarios, furthering their understanding of how Hi1a can be used as a therapeutic intervention.

Q: How does Hi1a compare to other cardioprotective drugs in development?
A: Hi1a is just as effective in protecting the heart as the only cardioprotective drug that has reached Phase 3 clinical trials. However, unlike the other drug, Hi1a interacts specifically with the injured area of the heart during an attack, minimizing the risk of adverse reactions in healthy regions.

Q: Who first identified the potential of Hi1a?
A: Professor Glenn King, known for his work in developing insecticides from spider venom, first identified the potential of Hi1a.

Q: Has the safety and effectiveness of Hi1a been confirmed?
A: Yes, independent contract research organizations have conducted safety studies that confirm the effectiveness and safety of Hi1a as a potential therapeutic.

Q: Has Hi1a attracted funding for further development?
A: Yes, Infensa Bioscience, a company co-founded by the researchers, raised $23 million in funding in 2022 to further develop Hi1a for commercial purposes.

Q: What is the current state of cardiovascular disease and existing treatments?
A: Cardiovascular disease is currently the leading global cause of death, with heart attacks and strokes being major contributors. There are currently no existing drugs on the market to prevent the damage caused by these events.

Q: What potential impact could Hi1a have on individuals suffering from heart disease?
A: The development of an effective treatment like Hi1a could have a profound impact on millions of individuals suffering from heart disease worldwide, as it could potentially limit heart and brain damage during cardiovascular events.

Definitions:
Hi1a: A drug candidate derived from spider venom that has shown potential in protecting cells from the damage caused by heart attacks and strokes.
Cardioprotective: Referring to actions or substances that protect the heart from damage or injury.
Preclinical tests: Tests conducted on animals or cells to evaluate the safety and effectiveness of a potential treatment before it can be tested on humans.
Phase 3 clinical trials: The third stage of clinical trials in which the potential treatment is tested on a larger group of patients to determine its efficacy, safety, and side effects.
Oxygen deprivation: A condition in which the body or tissue is deprived of an adequate supply of oxygen.
Contract research organizations: Independent companies that provide research services to support the development of new drugs or treatments.
Commercial purposes: Referring to the development and production of a treatment or drug for sale and distribution in the market.

Related Links:
Institute for Molecular Bioscience
University of Queensland
American Heart Association

All Rights Reserved 2021
| .
Privacy policy
Contact